



ASX ANNOUNCEMENT

Pro Rata Accelerated Non-Renounceable Entitlement Offer Offer Document and Shareholder Access Information

MELBOURNE, Australia (10 June 2022) - Lumos Diagnostics Holdings Limited (ASX: **LDX**) (**Lumos** or the **Company**) announces that today, Friday 10 June 2022, is the Opening Date of the retail component of its Accelerated Non-Renounceable Entitlement Offer (Retail Entitlement Offer), and that the Company will today issue relevant documents to Eligible Shareholders.

This announcement follows the Company's notification to the market on 6 June 2022 of launch of the Institutional and Retail Entitlement Offer.

A copy of the relevant documents Eligible Shareholders are to receive are enclosed with this notice, comprising:

- Sample Letter to Eligible Shareholders;
- Prospectus (as announced to the ASX on 6 June 2022 and can be found here: https://lumosdiagnostics.com/wp-content/uploads/2022/06/2390748_Prospectus.pdf); and
- Sample Retail Entitlement Offer Application Form.

Also accompanying this notice is a copy of the letter which will be dispatched today to Ineligible Shareholders.

Eligible Shareholders who have provided an email address for communications will receive an email containing a link to their individual Entitlement documents. Eligible Shareholders who have not provided an email address for communications will receive a hard copy personalised Covering Letter to their registered postal address, containing details of how to access their individual Entitlement documents.

The closing date of the Entitlement Offer is 5:00pm (AEST) on Thursday, 23 June 2022. Lumos reserves the right to vary the closing date without further notice.

Shareholders should consider the Prospectus in full before deciding whether to participate in the Retail Entitlement Offer.

Shareholders requiring information about the Retail Entitlement Offer may contact the Company Secretary Information Line on +61 3 9087 1598.

This announcement is authorised for release by the Lumos Disclosure Committee.

###

About Lumos Diagnostics

Lumos Diagnostics specializes in rapid, cost-effective, and complete point-of-care (POC) diagnostic test technology to help healthcare professionals more accurately diagnose and manage medical conditions. Lumos offers customized assay development and manufacturing services for POC tests and proprietary digital reader platforms. Lumos also directly develops, manufactures, and commercializes novel Lumos-branded POC tests that target infectious and inflammatory diseases.

For more information visit lumosdiagnostics.com.

Media Contact:

Matthew Wright
Director, NWR Communications
matt@nwrcommunications.com.au
+61 451 896 420

Investor Relations Contact:

Matthijs Smith
ir@lumosdiagnostics.com
+61 411 137 080

Company Registered Office:

Lumos Diagnostics Holdings Ltd
Level 4, 100 Albert Rd
South Melbourne, VIC 3205
+61 3 9087 1598

Important Notices

This announcement is issued by Lumos Diagnostics Holdings Limited. This announcement is not a prospectus or offering document under Australian law or under any other law. It is for information purposes only and does not constitute an offer, invitation, solicitation, advice or recommendation to subscribe for, retain or purchase any entitlements or securities in Lumos Diagnostics Holdings Limited in any jurisdiction. This letter does not constitute financial product advice and does not and will not form any part of any contract for the acquisition of Lumos Diagnostics Holdings Limited ordinary shares.

Not for Distribution or Release in the United States

This letter does not constitute an offer to sell, or a solicitation of an offer to buy, any securities in the United States or to, or for the account or benefit of, any person in the United States or in any other jurisdiction in which such an offer would be illegal. The New Shares have not been, nor will be, registered under the U.S. Securities Act of 1933 as amended (U.S. Securities Act) or under the securities laws of any state or other jurisdiction of the United States. The New Shares may not be issued to, purchased or traded by, or taken up by, any person in the United States or any person acting for the account or benefit of a person in the United States except pursuant to an exemption from, or in a transaction not subject to, the registration requirements of the U.S. Securities Act and applicable U.S. state securities laws.